ArticleDiscover oncology2025
Whole-exome sequencing in a patient with a history of esophageal squamous cell carcinoma to discriminate recurrent disease from a second primary tumor.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
A 52-year-old man who previously underwent McKeown esophagectomy to treat lower thoracic esophageal squamous cell carcinoma (ESCC) and subsequently received radical radiotherapy to treat cervical lymph node malignancy (squamous cell carcinoma on pathology; presumed to be metastasis of the primary tumor) presented with recurrent cervical lymphadenopathy during periodic reexamination. On admission, gastroscopy revealed a 0.5 × 0.5-cm lesion on the cervical remnant esophagus, and biopsies of both the lesion and cervical lymph nodes confirmed SCC. Whole-exome sequencing revealed that there were no comutations between the tumor samples from the primary ESCC from 2017 and the other malignancies (tumor samples from the remaining ESCC in 2022 and cervical lymph node malignancies on two occasions). Interestingly, the first and second cervical lymph node malignancies and the tumor in the cervical remnant esophagus shared many comutations, suggesting that the tumor in the cervical remnant esophagus is a second primary tumor with cervical lymph node metastasis and is not amenable to radical radiotherapy. Significant regression of lymphadenopathy was achieved after 2 cycles of immunochemotherapy; however, the patient declined further surgical intervention. Six months later, positron emission tomography-computed tomography (PET-CT) revealed tumor progression with multiple metastases. Herein, we show the importance of regular examination of the remnant esophagus and the significance of whole-exome sequencing for distinguishing the source of malignancy, which could aid in the formulation of appropriate treatment plans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.